Eli Lilly and Co. has agreed to acquire AtaiBeckley, a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, to advance the drugmaker’s push into psychedelic-based research. The acquisition comes as the federal government has pursued actions to advance…
Pharmacy
Maryland pharmacists will gain expanded authority to participate in opioid use disorder treatment under a new state law taking effect July 1. House Bill 838 eliminates the requirement that authorized prescribers submit prescriber-pharmacist agreements to the applicable health occupations board.…
More than 14,700 bottles of Duloxetine — commonly prescribed for individuals with depression and anxiety conditions — were recalled nationwide after the antidepressant was found to contain N-nitroso-duloxetine impurity above the FDA’s recommended interim limit. Breckenridge Pharmaceutical initiated a voluntary…
In 2024, nearly 30% of residents in Massachusetts with commercial insurance filled a prescription to treat a behavioral health condition, as diagnoses and medication usage increased across all demographics, WWLP reported June 11. Here are four things to know:
Grand Mental Health, a Tulsa, Okla.-based behavioral health organization, has officially entered the pharmacy space — a move its leadership says is both a financial strategy and a direct extension of its mission to serve some of Oklahoma’s most underserved…
Advertisement
The White House is preparing an executive order to expand federal research into ibogaine, a psychedelic drug used in some countries to treat PTSD, CBS News reported April 16. The Trump administration plans to keep ibogaine classified as a Schedule…
GSK, a biopharmaceutical company, has withdrawn its application to the FDA for leucovorin calcium tablets, months after the White House promoted the drug as a potential treatment for autism-related symptoms, The Wall Street Journal reported April 10. The FDA approved…
At Cedar Crest Hospital in Belton, Texas, pharmacy leadership spent the past year focused on one core shift: modernizing medication distribution to improve safety in a high-risk psychiatric setting. Edith Okolo, PharmD, director of pharmacy, said 2025 marked a major…